Lead program in glioblastoma

An opportunity to develop both internal and partnered programs

The Pin™ Platform provides a unique opportunity to conduct both proprietary in-house development programs as well as forming partnerships to exploit the modularity of the concept.

CYTEA BIO has elected to initiate a lead development program using armed human allogeneic natural killer cells with Pin™ engineered  anti-EGFR antibody  for the treatment of glioblastoma multiforme.

GLIOBLASTOMA

~50k

New patients diagnosed a year

12-15

Months of median overall survival

Effector cell (target)

Indication

Research

ind-enabling

Clinical

NK (EGFR)

Glioblastoma multiforme

Pin™ anti-EGFR + eNK

NK (EGFR)

EGFR + solid tumors

Pin™ anti-EGFR + eNK

TBD

Solid tumors, auto-immune & inflammatory diseases

TBD

NK (CD20)

Lymphoma

Pin™ anti-CD20 + eNK

Challenges and Innovations in Glioblastoma Multiforme Treatment

Applications & Grades

CYTEA BIO envisions overcoming obstacles in cancer treatment through cellular immunotherapy, leading the development of a novel product based on its Pin™ Platform for Glioblastoma Multiforme (GBM). This groundbreaking approach targets residual tumor depletion and is likely to delay recurrence as a second-line treatment post-surgery. Tailoring targeting ligands to tumor characteristics determined by biopsy enhances precision. Success in establishing the Pin™ Platform for GBM could pave the way for more effective generations of products, establishing a valuable asset base for CYTEA BIO. Demonstrating safety and efficacy in GBM treatment not only addresses a critical patient need but also presents opportunities for broader clinical applications, benefiting patients across various cancers.